Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Abstract

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

What is claimed is: 
     
         1 - 38 . (canceled) 
     
     
         39 . Crystalline N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) characterized as Form C, wherein the Form C is characterized by all of the following peaks in an XRPD pattern: about 6.2, about 7.5, about 8.3, about 12.4, about 14.6, about 17.9, about 20.5 and about 20.9 degrees as measured on a 2-Theta scale, and wherein the Form C is isolated and purified. 
     
     
         40 . A pharmaceutical composition comprising Form C according to  claim 39 , and a pharmaceutically acceptable adjuvant or carrier. 
     
     
         41 . Crystalline N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) characterized as Form C, wherein the Form C is characterized by a peak having a 2-Theta value from about 6.0 to about 6.4 degrees in an XRPD pattern, a peak having a 2-Theta value from about 7.3 to about 7.7 degrees in an XRPD pattern, a peak having a 2-Theta value from about 8.1 to about 8.5 degrees in an XRPD pattern, a peak having a 2-Theta value from about 12.2 to about 12.6 degrees in an XRPD pattern, a peak having a 2-Theta value from about 14.4 to about 14.8 degrees in an XRPD pattern, a peak having a 2-Theta value from about 17.7 to about 18.1 degrees in an XRPD pattern, a peak having a 2-Theta value from about 20.3 to about 20.7 degrees in an XRPD pattern, and a peak having a 2-Theta value from about 20.7 to about 21.1 degrees in an XRPD pattern; and wherein the Form C is isolated and purified.